Inovio Pharmaceuticals Announces Data From Phase 2 Glioblastoma Multiforme Study With INO-5401 In Combination With PD-1 Inhibitor Libtayo; Data Showed 80% 6-Month Progression-Free Survival
luke@benzinga.com